Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
licensing
Pharma
Zymeworks pivots to become 'royalty-driven' drugmaker
Having found success with its out-licensed cancer med Ziihera, Zymeworks will apply the framework for that drug to all its products going forward.
Fraiser Kansteiner
Nov 18, 2025 8:25am
Novo Nordisk, AstraZeneca, Ono—Fierce Pharma Asia
Feb 21, 2025 8:45am
Novartis tasks Lindy to turn biologics into at-home injectables
Aug 28, 2024 10:18am
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
May 17, 2024 8:30am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am
